ReGelTec Honored as MedTech Innovator Breakthrough Medtech Startup
June 5, 2025 – Los Angeles
MedTech Innovator (MTI), the world’s largest and most impactful accelerator for medical technology startups, today announced the 64 companies selected for its highly competitive 2025 Accelerator Cohort. These companies, representing the top 4% of nearly 1,500 global applicants, will participate in MTI’s flagship four-month program designed to de-risk innovation and accelerate the path to U.S. market success.
ABOUT REGELTEC, INC:
ReGelTec, Inc. is a clinical stage medical device company commercializing HYDRAFIL, a percutaneous treatment for low back pain due to degenerative disc disease. The company was formed when a team of chemical engineers with extensive experience in polymer science partnered with a cross-functional team of medical device professionals with multiple successful startup exits. Once approved, the HYDRAFIL System will offer patients suffering from chronic back pain due to degenerative disc disease a minimally invasive treatment option beyond traditional conservative care. HYDRAFIL is an investigational device, limited by United States law to investigational use.
